Dermata Therapeutics, Inc. (DRMA)
| Market Cap | 5.07M +12.0% |
| Revenue (ttm) | n/a |
| Net Income | -7.56M |
| EPS | -8.16 |
| Shares Out | 4.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,691 |
| Open | 1.250 |
| Previous Close | 1.300 |
| Day's Range | 1.250 - 1.320 |
| 52-Week Range | 1.100 - 8.645 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+693.65%) |
| Earnings Date | May 14, 2026 |
About DRMA
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for DRMA stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
Dermata receives notice of acceptance of Australian patent application
Dermata Therapeutics (DRMA) announced the Australian Patent Office has accepted its patent application for its topical dermal filler program utilizing its BDS. The patent, entitled “Compositions for t...
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers - - The Company also has allowed and issued patents in the US, Australi...
Dermata Therapeutics price target lowered to $4 from $10 at Maxim
Maxim lowered the firm’s price target on Dermata Therapeutics (DRMA) to $4 from $10 and keeps a Buy rating on the shares. The company’s Q4 results saw operating expenses slightly
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome - - Dermata plans to launch its first DTC product, our Foundat...
Dermata Therapeutics appoints Kyra Peckaitis as VP, marketing
Dermata Therapeutics (DRMA) announced the appointment of Kyra Peckaitis as Vice President, Marketing. Ms. Peckaitis is a multi-disciplinary brand marketer and will lead Dermata’s new brand launch, Tom...
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand - SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") ...
Dermata Therapeutics announces release of Tome Skincare
Dermata Therapeutics (DRMA) announces the branding of its latest innovation in skincare: Tome, which aims to introduce “skintech at home”. The Company’s Tome skincare line will bring intentionally dev...
Dermata Opens a New Chapter with the Release of Tome Skincare
-The oldest new thing in skincare - - Dermata expects to launch its first product in the middle of 2026 - SAN DIEGO, CA / ACCESS Newswire / March 5, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nas...
Dermata Therapeutics files to sell 1.48M shares of common stock for holders
17:03 EST Dermata Therapeutics (DRMA) files to sell 1.48M shares of common stock for holders
Dermata Therapeutics receives notice of grant of patent for acne treatment
Dermata Therapeutics (DRMA) announced the Australian Patent Office has granted its patent application for its Spongilla technology combination as a method for treating acne. The patent, entitled “Comp...
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne Dermata expects to launch a new once-weekly, over-the-coun...
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 29, 2025 / Dermata Th...
Dermata Therapeutics prices 2.02M shares at $2.04 in private placement
Dermata Therapeutics (DRMA) entered into definitive agreements for the issuance and sale of an aggregate of 2,022,062 shares of common stock, series C warrants to purchase up to 2,022,062 shares
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 24, 2025 / Dermata Th...
Dermata Therapeutics to reveal brand name for OTC skincare business
Dermata Therapeutics (DRMA) will soon reveal its new brand name for its over-the-counter skincare business representing its evolution toward a more direct, science-first era of dermatologic innovation...
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today annou...
Dermata Therapeutics files $100M mixed securities shelf
11:34 EST Dermata Therapeutics (DRMA) files $100M mixed securities shelf
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments - - Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongi...
Dermata says Australian Patent Office accepts Spongilla tech application
Dermata Therapeutics (DRMA) announced the Australian Patent Office has accepted Dermata’s patent application for its Spongilla technology combination as a method for treating acne. The accepted patent...
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne - - Dermata expects to launch a new once-weekly, Over-the-Coun...
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / September 17...
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18 th Dermata invites individual and institutional investors, as wel...
Dermata Therapeutics announces strategic pivot to OTC skin care treatments
Dermata Therapeutics (DRMA) announced a strategic pivot to prioritize the development and distribution of over-the-counter pharmaceutical dermatology focused products that can be sold directly to cons...
Dermata Therapeutics withdraws IND application for XYNGARI
As part of the Company’s strategic shift into the OTC marketplace, it has withdrawn its investigational new drug application for XYNGARI with FDA. The Company believes this strategic decision will
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today ann...